TD Cowen analyst Tyler Van Buren has maintained their bullish stance on TYRA stock, giving a Buy rating today.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tyler Van Buren has given his Buy rating due to a combination of factors including Tyra Bioscience’s progress in their clinical trials and their financial stability. The company has successfully dosed the first patient in the Phase II SURF302 study for their FGFR3 inhibitor, dabogratinib, targeting non-muscle invasive bladder cancer, and is on track to begin dosing in the Phase II BEACH301 trial for achondroplasia in the third quarter.
Furthermore, Tyra Bioscience is optimizing dabogratinib dosing for future studies, demonstrating a proactive approach in their research and development efforts. The company’s strong cash position ensures that they have the necessary resources to continue funding these programs, providing confidence in their ability to achieve their clinical milestones. These strategic advancements and financial preparedness underpin Van Buren’s positive outlook and Buy rating for Tyra Bioscience.
In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $30.00 price target.